Infections in acute myeloid leukemia: An analysis of 382 febrile episodes

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1037-1045

  Gupta, Ajay ^a   Singh, Mansher ^a   Singh, Harkirat ^a   Kumar, Lalit ^a   Sharma, Atul ^a   Bakhshi, Sameer ^a   Raina, Vinod ^a   Thulkar, Sanjay ^a  

^a INSTITUTE ROTARY CANCER HOSPITAL   (India)

Author keywords

Acute myeloid leukemia; Developing countries; Febrile neutropenia; Fungal infections

Indexed keywords

AMIKACIN; AMPHOTERICIN B; CEFTAZIDIME; CIPROFLOXACIN; CYTARABINE; DAUNORUBICIN; FLUCONAZOLE; IMIPENEM; ITRACONAZOLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; TIMENTIN; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BRAIN MALARIA; CHEST INFECTION; CHILD; CONTINUOUS INFUSION; DEATH; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GRAM NEGATIVE INFECTION; HUMAN; HYPOTENSION; LUNG INFECTION; LUNG INFILTRATE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALARIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYCOSIS; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SEPSIS; SINUSITIS; TUBERCULOUS SPONDYLITIS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FEVER; HUMANS; INFECTION; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEUTROPENIA; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 79951775311     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9330-9     Document Type: Article

References (41)

1. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new direction for its management. Cancer. 2004;100:228-37. (Pubitemid 38063629)
2. Gerson SL, Talbot GH, Hurwitz S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100:345-51. (Pubitemid 14156535)
3. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34:730-51. (Pubitemid 34194843)
4. National Committee for Clinical Laboratory Standards. Performance Standards for antimicrobial disk susceptibility tests, approved standard. 7th ed. Villanova, PA: NCCLS; 2000. (document M2-A7).
5. Ascioglu S, Rex RH, de Pauw B, et al. Invasive fungal infections: cooperative group of the european organization for research and treatment of cancer; mycoses study group of the national institute of allergy and infectious diseases. Defining opportunistic invasive fungal infections in immune-compromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
6. Jagarlamudi R, Kumar L, Kochupillai V, et al. Infections in acute leukemia: an analysis of 240 febrile episodes. Med Oncol. 2000;17:111-6. (Pubitemid 30367838)
7. Kumar L, Kochupillai V, Bhujwala RA. Infections in acute myeloid leukemia study of 184 episodes. J Assoc Phys India. 1992;40:18-20.
8. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European organization for research and treatment of cancer and leukemia cooperative group. J Clin Oncol. 1996;14:2150-9. (Pubitemid 26230119)
9. De Lalla F. Antibiotic treatment of febrile episodes in neutropenic cancer patients. Drugs. 1997;53:789-803.
10. Godwin JE, Kopecky JK, Head DR, et al. A double-blind placebocontrolled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood. 1998;91:3607-15. (Pubitemid 28225726)
11. Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood. 1998;91:2722-30. (Pubitemid 28227521)
12. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood. 1997;90:4710-8. (Pubitemid 28007183)
13. Malagola M, Peli A, Damiani D, et al. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Euro J Haematol. 2008;81:354-63.
14. Cornet M, Fleury L, Maslo C, et al. Epidemiology of invasive aspergillosis in France: a six-year multicentric survey in the Greater Paris area. Invasive aspergillosis surveillance network of the assistance Publique-Hopitaux de Paris. J Hosp Infect. 2002;51:288-96. (Pubitemid 38001879)
15. Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEI-FEM-2004 study. Haematologica. 2006;91:1068-75. (Pubitemid 44208634)
16. Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia. 2004;18:72-7. (Pubitemid 38159441)
17. Offidani M, Corvatta L, Malerba L, et al. Risk assessment of patients with hematologic malignancies who develop fever accompanied by pulmonary infiltrates: a historical cohort study. Cancer. 2004;101:567-77. (Pubitemid 38970608)
18. Klastersky J, Ameye L, Maertens J, et al. Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents. 2007;30(Suppl 1): S51-9.
19. Cherif H, Kronvall G, Björkholm M, et al. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J. 2003;4:420-6. (Pubitemid 38088787)
20. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Inf Dis. 2003;36:1103-10. (Pubitemid 36553108)
21. Morris PG, Hassan T, McNamara M, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. Support Care Cancer. 2008;16(9):1085-8.
22. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta analysis. Clin Inf Dis. 1996;23:795-805. (Pubitemid 26331127)
23. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic patients: a meta analysis. J Clin Oncol. 1998;16:1179-87. (Pubitemid 28108756)
24. Rubio M, Palau L, Vivas JR, et al. Predominance of gram positive micro-organisms as a cause of septicemia in patients with hematologic malignancies. Infect Control Hosp Epidemiol. 1994;15:101-4.
25. Gardner A, Mattiuzzi G, Faderl S, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. J Clin Oncol. 2008;26(35):5684-8.
26. Sanpakit K, Phuakpet K, Veerakul G, et al. Evaluation of guideline for treatment of febrile neutropenia in pediatric cancer at Siriraj Hospital. J Med Assoc Thai. 2005;88(Suppl 8): S124-34. (Pubitemid 43175631)
27. Paul M, Gafter-Gvili A, Leibovici L, et al. The epidemiology of bacteremia with febrile neutropenia: experience from a single center, 1988-2004. Isr Med Assoc J. 2007;9:424-9. (Pubitemid 46979142)
28. Kitamura K, Takaku F, Miyazaki T, et al. Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders. Jpn J Antibiot. 1991;44:979-86.
29. Fukuda M, Hirashima K. Clinical evaluation of combination therapy with sulbactam/cefoperazone and amikacin sulfate for infections associated with hematological disorders. Jpn J Antibiot. 1993;46:912-7. (Pubitemid 23353229)
30. Takashima T, Tsuda S, Misawa S, et al. A combined sulbactam/cefoperazone and amikacin therapy for the treatment of infections complicated with hematological diseases. Jpn J Antibiot. 1993;46:251-8. (Pubitemid 23142143)
31. Toyama K, Torii Y, Aoki I, et al. Clinical evaluation of sulbactam/cefoperazone for severe infections associated with hematological disorders. Jpn J Antibiot. 1992;45:1003-8.
32. Kawai Y, Ueda T, Iwasaki H, et al. Clinical evaluation of sulbactam/cefoperazone for infections during the chemotherapy of hematologic malignancy. Jpn J Antibiot. 1994;47:1196-201. (Pubitemid 24306496)
33. Worth LJ, Thursky KA, Seymour JF, et al. Slavin M A Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk. Eur J Hematol. 2007;79:226-33. (Pubitemid 47241068)
34. Todeschini G, Tecchio C, Borghero C, et al. Association between Enterococcus bacteraemia and death in neutropenic patients with haematological malignancies. J Infect. 2006;53:266-73. (Pubitemid 44424268)
35. Kapur D, Dorsky D, Feingold JM, et al. Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2000;25:147-52. (Pubitemid 30087983)
36. Poutsiaka DD, Skiffington S, Miller KB, et al. Daptomycin in the treatment in the treatment of vancomycin resistant Enteroccus faecium bacteremia in neutropenic patients. J Infect. 2007;54:567-71. (Pubitemid 46731225)
37. Smith PF, Birmingham MC, Noskin GA, et al. Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant grampositive infections in cancer patients with neutropenia. Ann Oncol. 2003;14:795-801. (Pubitemid 36621782)
38. Linden PK, Moellering RC, Wood CA, et al. Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/ dalfopristin. Clin Inf Dis. 2001;33:1816-23. (Pubitemid 33105119)
39. Shawgi S, Kumar L, Kochupillai V, et al. Evaluation of pulmonary infiltrates in patients with hematological malignancies using fibreoptic bronchoscopy and bronchoalveolar lavage. Ind J Med Pediatr Oncol. 2004;25:10-21.
40. Koskenvuo M, Mattanen M, Rahiala J, et al. Respiratory viral infections in children with leukemia. Pediatr Infect Dis J. 2008;27(11):974-80.
41. Mishra P, Kumar R, Mahapatra M, et al. Tuberculosis in acute leukemia: a clinico-hematological profile. Hematology. 2006;11:335-40. (Pubitemid 46957656)